ASCO 2023 | LINKER-MM1: linvoseltamab in patients with R/R multiple myeloma
Hans Lee, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses findings from LINKER-MM1 (NCT03761108), a study on the efficacy and safety of the bispecific antibody linvoseltamab in patients with relapsed/refractory (R/R) multiple myeloma. The study included two Phase II cohorts with different doses (50 mg and 200 mg) to determine the optimal dose. The primary endpoint was the objective response rate (ORR), and secondary endpoints included duration of response (DoR) and measurable residual disease (MRD) status. Results showed that the 200 mg dose demonstrated higher efficacy, including in high disease burden subgroups. Safety profiles were consistent across the doses. The recommended dose for further development is 200 mg. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
